Alexion will invest €450 million to expand to Dublin

12/05/2015 - 2 minutes

Alexion Pharmaceuticals will travel across the ocean to build its first ever biologics manufacturing facility outside the United States. This €450 million, four-year project, will be constructed at the Alexion’s College Park site in Blanchardstown (Ireland) and should create approximately 200 additional full-time jobs. This will bring Alexion’s total workforce in Ireland to almost 500 employees.

The first phase of the College Park facility is expected to be operational by the end of the year. It comprises Global Supply Chain HQ, laboratories, packaging and warehousing operations. The company has worked closely with the Department of Jobs and IDA Ireland on the development of its operations in the country.

The new facility’s personnel will support the production and distribution of Alexion’s medicine, Soliris, as well as its strong pipeline of biologics medicines. Soliris, approved for the treatment of two ultra-rare diseases (atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria) is also well-known for being the world’s most expensive drug.

This is one of the largest investments in healthcare in the history of the Irish state. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member